Clinical and Pharmacological Aspects of Resistance to Eradication Therapy of Helicobacter Pylori Infection
Abstract
Despite the evidence of the effectiveness of modern medicines, which are included in modern schemes of eradication therapy, against Helicobacter pylori, the problem of growth of microorganism resistance to them is relevant not only for various regions of the Russian Federation; it also has an international and even intercontinental spread. The article presents modern information on Helicobacter pylori pathogenicity, the prevalence and development mechanisms of its resistance to antibiotics widely used for eradication, the contradictions in the information on indications, duration of use, anti-Helicobacter pylori treatment regimens and dosage in modern clinical guidelines and instructions for medical use.
About the Authors
S. Yu. Serebrova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
A. B. Prokofiev
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
N. N. Eremenko
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
M. V. Zhuravleva
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
T. A. Alexandrova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
References
1. Jaka Н, Rhee J.A., Ostlundh L. et al. The magnitude of antibiotic resistance to Helicobacter pylori in Africa and identified mutations which confer resistance to antibiotics: systematic review and metaanalysis. BMC Infect Dis 2018; 18: 193.
2. Саблин O.A., Илшишина ТА. Проблема резистентности Helicobacter pylori к кларитромицину. Гастроэнтерология (приложение Consilium medicum). - 2009. - № 2. - С. 4-8. / Sablin ОА., Ilchishina ТА. Problema rezistentnosti Helicobacter pylori k klaritromitsinu. Gastroenterologiya (prilozhenie Consilium medicum). 2009; 2:4—8.
3. Malfertheiner P., Megraud F., OMorain CA. et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2016; 0:1-25.
4. Ghotaslou R, Leylabadlo HE., Asl Y.M. Prevalence of antibiotic resistance in Helicobacter pylori: a recent literature review. World J Methodol 2015; 5 (3): 164-174.
5. Khademi F., Poursina F., Hosseini E. et al. Helicobacter pylori in Iran: a systematic review on the antibiotic resistance. Iran J Basic MedSci2015; 18(1): 2.
6. Hunt R, Xiao S., Megraud F. et al. Helicobacter pylori in developing countries. World gastroenterology organisation global guideline. J Gastrointestin Liver Dis 2011; 20 (3): 299—304.
7. Glupczynski Y., Megraud F., Lopez-Brea M., Andersen L. European multicenter survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20 (11): 820-823.
8. Frenck R W., Clemens J. Helicobacter in the developing world. Microbes Infect 2003; 5 (8): 705-713.
9. Megraud F. H.pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53 (9): 1374-1384.
10. Abadi ТВ. Resistance to clarithromycin and gastroenterologisfs persistence roles in nomination for Helicobacterpylori as high priority pathogen by World Health Organization. World J Gastroenterol 2017; 23 (35): 6379-6384.
11. Gebeyehu E., Bantie L., Azage M. Inappropriate use of antibiotics and its associated factors among urban and rural communities of Bahir Dar city administration, Northwest Ethiopia. PLoS One 2015; 10 (9): e0138179.
12. Giorgio F., Principi M., De Francesco V. et al. Primary clarithromycin resistance to Helicobacterpylori: is this the main reason for triple therapy failure. World J Gastrointest Pathophysiol 2013; 4 (3): 43—46.
13. Organization W.H. Guidelines for the management of sexually transmitted infections. Geneva: WHO; 2001. In: WHO/HIV_AIDS/2001, 01. 2008. Available from http://www.who.int/hiv/pub/sti/en/STIGuidelines2003.pdf. Accessed 20 July 2006.
14. De Francesco V., Giorgio F., Hassan C. et al. Worldwide H.pylori Antibiotic Resistance: a Systematic Review. J Gastrointestin Liver Dis 2010; 19 (4): 409-414.
15. Поздеев O.K., Морозова Л.Г., Поздеева А. О. и др. Мониторинг первичной антибиотикорезистентности штаммов Helicobacter pylori, выделенных в Республике Татарстан в 2008—2013 гг. Клин микробиол антимикроб химиотер. — 2016. — № 2. — С. 146—151. / Pozdeev O.K., Morozova L. G., Pozdeeva A. O. i dr. Monitoring pervichnoy antibiotikorezistentnosti shtammov Helicobacter pylori, vydelennykh v Respublike Tatarstan v 2008—2013 gg. Klin mikrobiol antimikrob khimioter 2016; (2): 146—151. [in Russian]
16. Дехнич H.H., Костякова E.A., Пунин AA. и dp. Антибиотикорезистентность H.pylori: результаты микробиологического регионального исследования. Рос журн гастроэнтерол гепатол колопроктол. — 2011. - Т. 21. - № 2. - С. 37-42. / Dekhnich N.N., Kostyakova Е.А., Punin А.А. i dr. Antibiotikorezistentnost' H.pylori: rezul'taty mikrobiologicheskogo regional'nogo issledovaniya. Ros zhum gastroenterol gepatol koloproktol 2011; 21 (2): 37—42. [in Russian]
17. Дехнич H.H., Иватик H.B., Козлов P.С. и др. Чувствительность штаммов H.pylori к антимикробным препаратам в г. Смоленске в 2015—2016 гг. Рос жури гастроэнтерол гепатол колопроктол. — 2016. - № 6. - С. 24-31. / Dekhnich N.N., IvanchikN. К, Kogjov R.S. i dr. Chuvstvitel'nost' shtammov H.pylori k antimikrobnym preparatam v g. Smolenske v 2015—2016 gg. Ros zhurn gastroenterol gepatol koloproktol 2016; 6: 24—31. [in Russian]
18. Саблин O.A., Михайлов H.B., Юрин M.B. и др. Первичная резистентность Helicobacter pylori к антибиотикам в Санкт-Петербурге. Экс- пер клин фармакол. — 2012. № 8. — С. 18—23. / Sablin О.А., Mikhaylov N. V., Yurin М. V. i dr. Pervichnaya rezistentnost' Helicobacter pylori k antibiotikam v Sankt-Peterbuige. Eksper klin farmakol 2012; 8: 18—23. [in Russian]
19. Симаненков В.И., Захарова Н.В., Жебрун А.В. и др. Резистентность Helicobacter pylori к антимикробным препаратам по результатам бактериологического тестирования. Леч врач. — 2015. — № 4. — С. 91—95. / Simanenkov V.I., Zakharova N.V., Zhebrun А.В. i dr. Rezistentnost' Helicobacter pylori k antimikrobnym preparatam po rezuftatam bakteriologicheskogo testirovaniya. Lech vrach 2015; (4): 91—95. [in Russian]
20. Sachs G. Gastric Infection by Helicobacter pylori. Curr Gastroenterol Rep 2011; 13 (6): 540-546.
21. PengX., SongZh., He L. etal. Gastric Juice-Based Real-Time PCR for Tailored Helicobacter Pylori Treatment: A Practical Approach. International J Med Sci 2017; 14 (6): 595-601.
22. Dean L. Esomeprazole Therapy and CYP2C19 Genotype. Med Gen Sum 2012; Last Update: March 8, 2016. https://www.ncbi.nlm.nih.gov/books/NBK100896/
23. Leclercq R., Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 9: 2727-2734.
24. ErahP.O., GoddardA.E, Barrett D.A. etal. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997; 39: 5-12.
25. Денисенко Н.П. Оптимизация фармакотерапии больных с язвенной болезнью на основе фармакогенетического тестирования — Дисс канд мед наук. — М.: 2018. / Denisenko N.P. Optimizatsiya farmakoterapii bol'nykh s yazvennoy bolezn'yu na osnove farmakogeneticheskogo testirovaniya — Diss kand med nauk. M.: 2018. [in Russian]
26. Iwamoto J. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori. Scand J Gastroenterol 2005; 40 (7): 783—793.
27. Kato S., Fujimura Sh., Udagawa H. et al. Antibiotic Resistance of Helicobacter pylori Strains in Japanese Children. Clin Microbiol 2002: 649-653.
28. Исаева E.HI. Резистентность H.pylori к антибактериальным препаратам и методы ее определения. Клин микробиол антимикроб химиотер. - 2010. - Т. 12. - № 1. - С. 57-66. / Isaeva G.SH Rezistentnost' H.pylori k antibakterial'nym preparatam i metody ее opredeleniya. Klin mikrobiol antimikrob khimioter 2010; 12 (1): 57-66. [in Russian]
29. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s0351bl.pdf
30. http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/conl487312104892.pdf
31. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050689s0221bl.pdf
32. http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/conl459313514484.pdf
33. Ших E.B., Maxoвa A.A., Шумянцева B.B., Демидова O.A. Фармакологическая регуляция активности изоферментов цитохромов Р450 ЗА4 и Р450 2С9 витаминами и природными соединениями. Ведомости НЦЭСМП. - 2016. - № 4. - С. 42-47. / Shikh Е. V., Makhova АА, Shumyantseva V.V., Demidova О.А. Farmakologicheskaya regulyatsiya aktivnosti izofermentov tsitokhromov P450 3A4 i P450 2C9 vitaminami i prirodnymi soedineniyami. Vedomosti NTSESMP 2016; 4: 42—47. [in Russian]
Review
For citations:
Serebrova S.Yu., Prokofiev A.B., Eremenko N.N., Zhuravleva M.V., Alexandrova T.A. Clinical and Pharmacological Aspects of Resistance to Eradication Therapy of Helicobacter Pylori Infection. Antibiot Khimioter = Antibiotics and Chemotherapy. 2018;63(9-10):31-38. (In Russ.)
Views:
314
Email this article 